Andreas Midbøe Hoff

Andreas Midbøe Hoff has a diverse work experience spanning multiple roles and companies. Andreas Midbøe is currently working at Nykode Therapeutics as the Team Manager and Senior Scientist since October 2021. Prior to this role, they served as a Senior Bioinformatics Scientist from April 2020 to November 2021 at the same company.

Before joining Nykode Therapeutics, Andreas worked at Oslo University Hospital where they held various positions. From April 2019 to April 2020, they worked as a Researcher. Andreas Midbøe also served as a Postdoctoral Fellow from December 2015 to March 2019, a PHD Candidate from February 2012 to November 2015, and a Scientific Associate from August 2011 to February 2012.

In 2016, Andreas worked as a Visiting Postdoc at the Broad Institute, specifically in the laboratory of Matthew Meyerson at Dana-Farber Cancer Institute & Broad Institute of Harvard and MIT. Andreas Midbøe'swork there focused on long-read sequencing technologies in cancer research with a specific focus on prostate cancer. This role lasted from November 2016 to October 2017.

In addition to their work in the research field, Andreas also served as a Deputy Board Member at Tekna from December 2015 to November 2016.

Andreas Midbøe'searliest recorded work experience was as an IAESTE Trainee at the University of Alberta in 2009.

Andreas Midbøe Hoff's work experience demonstrates their expertise in various scientific and research roles, particularly in the fields of bioinformatics and cancer research.

Andreas Midbøe Hoff completed their education in a chronological order. Andreas Midbøe obtained a Bachelor's degree in Biochemistry and molecular biology from the University of Oslo (UiO) in the years 2006 to 2009. Following that, they pursued a Master's degree in Molecular biology from the same university from 2009 to 2011. Finally, they completed their education by achieving a Doctor of Philosophy (PhD) degree in Cancer Genomics from the University of Oslo (UiO) in the years 2012 to 2015.